Russo Irene, Zorzetto Ludovica, Chiarion Sileni Vanna, Alaibac Mauro
Unit of Dermatology, University of Padua, Via Gallucci 4, 35128 Padova, Italy.
Istituto Oncologico Veneto I.R.C.C.S., Via Gattamelata 64, 35128 Padova, Italy.
Scientifica (Cairo). 2018 Dec 30;2018:5036213. doi: 10.1155/2018/5036213. eCollection 2018.
Melanoma is one of the most fatal cancers, and its incidence is increasing worldwide. Thanks to the better understanding of the molecular mechanisms involved in the pathogenesis of melanoma, recently new targeted agents have been developed. In this article, we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common cutaneous side effects observed during treatment with targeted and immunological therapies approved for advanced melanoma. We include discussion of BRAF/MEK inhibitors and immune-checkpoint inhibitors, notably CTLA-4 and PD-1 inhibitors.
黑色素瘤是最致命的癌症之一，其发病率在全球范围内呈上升趋势。由于对黑色素瘤发病机制中涉及的分子机制有了更深入的了解，最近已开发出新型靶向药物。在本文中，我们综述了在晚期黑色素瘤获批的靶向治疗和免疫治疗期间观察到的最常见皮肤副作用的临床表现、机制及管理方面的当前知识状况。我们讨论了BRAF/MEK抑制剂和免疫检查点抑制剂，尤其是CTLA-4和PD-1抑制剂。
